Trial reportEuropean journal of medical research2025
Clinical efficacy of ulinastatin and budesonide combination therapy in pelvic fracture complicated by pulmonary contusion.
Trial report in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study is to investigate the clinical efficacy of combination therapy with ulinastatin and budesonide as an adjuvant treatment in patients with pelvic fractures complicated by pulmonary contusion.
methodsA total of 136 individuals with pelvic fractures complicated by pulmonary contusion were enrolled from the Pelvic Ward of the Department of Trauma at Tianjin University Tianjin Hospital, Tianjin City, between July 2021 and July 2024. Participants were randomly assigned to a study group or a control group. The control group received budesonide suspension via aerosol inhalation (2 mg per dose, every 6 h). The study group received the same treatment along with intravenous administration of ulinastatin injection (1.0 × 10
resultsThe study group demonstrated statistically significant improvements in pulmonary contusion simple score, VAS, lung function and alveolar oxygenation indices, lung function-related cytokine levels, immune function, and oxidative stress indices compared to the control group (p < 0.05). However, no significant difference in overall complication rates was observed between the groups (p > 0.05).
conclusionsThe combination of ulinastatin and budesonide demonstrated significant efficacy in improving lung function indices, modulating immune responses, and reducing inflammation and oxidative stress in individuals with pelvic fractures complicated by pulmonary contusion. The combination therapy exhibited a favorable safety profile, may serve as a potential treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.